The role of postoperative radiotherapy (PORT) in combined small cell lung cancer (C-SCLC)
Metrics: PDF 962 views | HTML 1500 views | ?
Yu Men1,*, Yang Luo2,*, Yirui Zhai1, Jun Liang1, Qinfu Feng1, Dongfu Chen1, Zefen Xiao1, Zongmei Zhou1, Zhouguang Hui3 and Luhua Wang1
1Department of Radiation Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
2Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
3 Department of VIP Medical Services & Department of Radiation Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
*These authors contributed equally to this work
Zhouguang Hui, email: firstname.lastname@example.org
Luhua Wang, email: email@example.com
Keywords: carcinoma, combined small cell lung, surgery, radiotherapy, survival
Received: December 07, 2016 Accepted: March 22, 2017 Published: April 06, 2017
Purpose: To explore the value of radiotherapy in C-SCLC patients, especially in those receiving a radical resection.
Results: The differences of survivals between the postoperative radiotherapy (PORT) and non-PORT groups were not statistically significant. But analyzing the benefits in subgroups, PORT significantly improved OS (p = 0.015), DFS (p = 0.026), LRFS (p = 0.008) and DMFS (p = 0.030) in stage III patients. For the patients with N2 stage, all survivals of the PORT group were also statistically significantly higher than non-PORT group (p = 0.018, 0.032, 0.008, 0.042). Patients with more than 10% of metastatic lymph nodes could get a significant benefit survivals by receiving PORT (p = 0.033, 0.030, 0.025, 0.031). Having a systematic dissection of more than 17 lymph nodes was a subset which could get better OS and LRFS by receiving PORT (p = 0.045, 0.048).
Methods: Between Jan. 2004 to Dec. 2012, fifty-five patients diagnosed as C-SCLC after complete surgical resection in our center were retrospectively analyzed. The overall survival (OS), disease free survival (DFS), loco-regional recurrence free survival (LRFS), and distant metastasis free survival (DMFS) were calculated by Kaplan-Meier method.
Conclusions: PORT can significantly improve the survival of C-SCLC patients with resected pathological pN2 stage. For the patients with a large percent of metastatic lymph nodes, PORT can also improve survivals.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.